PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1741132
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1741132
CRISPR Genomic Cure Market is estimated to be valued at USD 4.62 Bn in 2025 and is expected to reach USD 17.04 Bn by 2032, growing at a compound annual growth rate (CAGR) of 20.5% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 4.62 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 20.50% | 2032 Value Projection: | USD 17.04 Bn |
The global CRISPR genomic cure market is a rapidly evolving sector within the global biotechnology industry. CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. This technology has the potential to transform the treatment of a wide range of diseases, including genetic disorders, cancers, and infectious diseases. The market for CRISPR genomic cures is driven by the increasing prevalence of genetic diseases and the growing demand for effective therapies. The technology's ability to modify genes with unprecedented precision has opened up new possibilities for the treatment of diseases that were previously considered untreatable. Moreover, advancements in CRISPR technology, such as the development of more efficient and safer gene-editing tools, are expected to further propel the growth of this market. The increasing investment in research and development activities, coupled with the growing collaboration between biotechnology companies and research institutes, is also contributing to the expansion of the global CRISPR genomic cure market. However, the market faces several challenges, including ethical and safety concerns related to gene editing, regulatory hurdles, and the high cost of developing and commercializing CRISPR-based therapies. Despite these challenges, the global CRISPR genomic cure market is expected to witness significant growth in the coming years, driven by the technology's immense potential to revolutionize healthcare. In conclusion, the global CRISPR genomic cure market represents a promising and dynamic field with the potential to bring about significant advancements in the treatment of various diseases.
Increasing prevalence of chronic disease, genetic disease, infectious diseases, neurological disease, blood disease, and metabolic disease, a growing geriatric population, growing demand for safe and effective treatment or therapies, increasing funding for cell and gene therapies, frequent approvals for gene therapies, the introduction of novel therapies, and increasing awareness among people about the global CRISPR genomic cure market are major factors expected to augment the growth of the global CRISPR genomic cure market during the forecast period.
For instance, in March 2021, scientists at UC San Francisco, UC Berkeley, and UCLA received U.S. Food and Drug Administration (FDA) approval to jointly launch an early-phase, first-in-human clinical trial of a CRISPR gene correction therapy in patients with sickle cell disease using the patient's own blood-forming stem cells. The therapy has the potential to transform sickle cell disease care by producing an accessible, curative treatment that is safer than the current therapy of stem cell transplant from a healthy bone marrow donor. Moreover, the therapy has the potential to prevent irreversible complications of the disease.